Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03640858|
Recruitment Status : Recruiting
First Posted : August 21, 2018
Last Update Posted : September 22, 2022
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Disease||Device: Theranova Dialyzer||Not Applicable|
Baxter Canada has an expanded hemodialysis (HDx) membrane called the "Theranova", which is capable of removing solutes of higher molecular weight. Although this clearly has biochemical advantages it is not known at this time if the removal of larger middle molecules can have a direct and immediate effect on patients reported symptoms and quality of life. In short, do be people actually feel better?
Given the way many QoL measurements fluctuate around the dialysis week, the investigators propose to utilize a dynamic tool. The investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL" an application based platform where patients self-report their symptoms with at least one hemodialysis treatment. Reports are generated immediately and in real-time, which cannot be accomplished with other symptom management tools. This allows the investigators to track study changes and benchmark observations to previously established baseline values. The investigators are excited to see if there is an imminent effect on how patients feel using the Theranova dialyzer.
The study is investigator initiated and the principal investigator has secured modest funding from Baxter to allow support for the core study team and the introduction and maintenance of the LEVIL evaluation platform at other centers. Baxter have also provided some dialyzer support, and will work with individual centers to ensure that there is no consumable increment of cost associated with participation.
The study is 60 weeks in length:
- LEVIL entries with at least one hemodialysis treatment each week for 60 weeks
- Blood sampling at 4 time points for all participants
- Implementation of Theranova dialyzer from weeks 5 through 16 and weeks 25 through 48
- Wash out period from weeks 17 through 24 and weeks 49 through 60
- Time to recovery question at the first treatment of weeks 1, 16, 24, and 48 for new participants
- 5-D Pruritus scale and Restless Legs Syndrome rating scale at the first treatment of weeks 1, 16, 24, and 48
- Echocardiogram prior to starting hemodialysis and at peak stress at baseline (within the first two weeks), with one treatment between weeks 12 to 16 which will occur mid-week, and with one treatment between weeks 44 to 48 which will occur mid-week (LHSC specific)
- CVInsight monitoring at baseline (within the first two weeks), with one treatment between weeks 2 to 16, 20 to 25, and with one treatment between weeks 44 to 48 (LHSC specific)
- Non-invasive assessment of cardiovascular risk using the AGE Reader within 1 hour of starting hemodialysis at baseline, with one treatment between weeks 12 to 16, 20 to 24, and with one treatment between weeks 44 to 48 which will occur mid-week (LHSC specific)
- Five Time Sit to Stand Test & 60-Second Chair Test at the second treatment of weeks 1, 16, 24, and 48
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||
Study visits take place within the patients' usual hemodialysis unit consistent with their routinely scheduled dialysis sessions. Beginning week 5 and 25 participants use the Theranova dialyzer until the end of the dialysis week on week 16 and 48. Participants answer 9 questions at least at one session regarding symptoms experienced since their last session using the LEVIL application. Furthermore, participants answer a single time to recovery question at the first treatment of weeks 1, 16, 24, and 48 to get more detailed information on recovery time after dialysis in addition to completing the 5-D Pruritus and the Restless Legs Syndrome scales.
Bloodwork is drawn at 4 intervals throughout the study for laboratory evaluation.
Participants have an echo at baseline and between weeks 12 to 16, 20-24 and 44-48 while on the Theranova dialyzer.
In addition to this, participants will have non-invasive monitoring of circulatory stress using the CVInsight contact device.
|Masking:||None (Open Label)|
|Official Title:||Interventional Study to Assess the Effect of Expanded Dialysis Using the Theranova Dialyzer on Patient Reported Symptoms Using the London Evaluation of Illness (LEVIL)|
|Actual Study Start Date :||May 8, 2019|
|Estimated Primary Completion Date :||January 31, 2023|
|Estimated Study Completion Date :||March 30, 2023|
Experimental: Patients receiving hemodialysis
A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
Device: Theranova Dialyzer
The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
- A change in larger middle molecule induced symptoms as assessed by the LEVIL application [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 46 ]The primary outcome will be a change (from patient's own baseline) in general well-being, pain, sleep, breathing, energy, appetite, itch, restless legs, and recovery from hemodialysis when using the Theranova dialyzer. These parameters will be measured using the LEVIL an electronic application based visual analog scale.
- A change in larger middle molecule clearance using the Theranova dialyzer [ Time Frame: First treatment of weeks 1, 14, and 46 ]The secondary outcome is a change in the clearance of large middle molecules which will be evaluated by measuring levels of beta-2 microglobulin, beta-12 binding globulin, free light chains (kappa, lambda), factor D, fibroblast growth factor 23, and interleukin 6.
- Correlation between large middle molecules and patient symptoms [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 54 ]Another secondary outcome is the relationship between the clearance of large middle molecules and specific symptoms reported by the patients using the LEVIL application.
- A change in symptoms with a change in dialyzer (usual to Theranova and vice versa) [ Time Frame: Beginning week 1 and ending at the end of the dialysis week on week 54 ]Another secondary outcome is if the time point where symptoms change with a change in dialyzer
- Effect on microcirculation and/or hemodialysis induced circulatory stress with the Theranova dialyzer [ Time Frame: Beginning week 3 and ending at the end of the dialysis week on week 14 and again week 23 and ending week 46 ]Another secondary outcome is the Theranova dialyzer effect on microcirculation and/or hemodialysis induced circulatory stress
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03640858
|Contact: Christopher McIntyre, MBBS DM||5196858500 ext 58502||Christopher.McIntyre@lhsc.on.ca|
|Contact: Jarrrin Penny, RN BSN||5196858500 ext 58765||Jarrin.Penny@lhsc.on.ca|
|Adam Linton Dialysis Unit||Recruiting|
|London, Ontario, Canada, N6A 5W9|
|Kidney Care Centre||Recruiting|
|London, Ontario, Canada, N6K 1M6|
|Contact: Jarrin Penny 5196858500 ext 58765|
|Principal Investigator:||Christopher McIntyre, MBBS DM||London Health Sciences Centre|